{"anticipatedPostingDate":"2027-06","denomUnitsSelected":"Participants","description":"To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of OS","reportingStatus":"NOT_POSTED","timeFrame":"Survival assessed every 2 months after RECIST defined radiological progression; assessed through study completion, up to 83 months","title":"Overall Survival (OS) Analysis","type":"SECONDARY"}